Клинический вестник ФМБЦ им. А.И. Бурназяна

ISSN 2782-6430 (print)

Федеральное государственное бюджетное учреждение
«Государственный научный центр Российской Федерации –
Федеральный медицинский биофизический центр имени А.И.Бурназяна»

Журнал издается на русском языке.
Формат – А4.
Периодичность выхода журнала –  4 раза в год.

Выпуск №2 2025 год

Подробнее
ВНИМАНИЮ АВТОРОВ СТАТЕЙ

Клинический вестник ФМБЦ им. А.И. Бурназяна. 2024. № 1

М.Н. Величко1, А.С. Умников1, А.М. Белякова2, А.В. Штурмин1

БИОЛОГИЧЕСКИЕ МЕТОДЫ ЛЕЧЕНИЯ В ТРАВМАТОЛОГИИ И ОРТОПЕДИИ

1ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России, Москва

2Первый МГМУ им.И.М.Сеченова Минздрава России, Москва

Контактное лицо: Белякова Анна Михайловна: md.belyakova@gmail.com

Резюме
Цель: провести аналитический обзор современных ортобиологических методов лечения болезней опорно-двигательного аппарата.
Материал и методы: проведен анализ зарубежных и отечественных источников по данной теме.
Результаты: на основании последних научных данных в представленном обзоре описаны ключевые ортобиологические методы лечения болезней опорно-двигательного аппарата, изучена эффективность их применения. Рекомендованы наиболее эффективные методики для клинической практики.
Заключение: проведенный нами анализ свидетельствует о том, что лечение болезней опорно-двигательного аппарата при помощи ортобиологических методов является актуальной проблемой и требует дальнейшего изучения наряду с его активным внедрением в повседневную практику.

Ключевые слова:  биологические методы лечения, травматология и ортопедия, болезни опорно-двигательного аппарата

Для цитирования: Величко М.Н., Умников А.С., Белякова А.М., Штурмин А.В. Биологические методы лечения в травматологии и ортопедии // Клинический вестник ФМБЦ им. А.И. Бурназяна 2024. №1. С. 44–51. DOI: 10.33266/2782-6430-2024-1-44-51

 

СПИСОК ИСТОЧНИКОВ

  1. Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noel D. Multipotentmesenchymal stromal cells in articular diseases. Best Pract Res ClinRheumatol. 2008;22(2):269–84.
  2. Jorgensen C, Noel D. Mesenchymal stem cells in osteoarticular diseases. Regen Med. 2011; 6(6 Suppl):44–51.
  3. Mifune Y, Matsumoto T, Takayama K, Ota S, Li H, Meszaros LB, Usas A, Nagamune K, Gharaibeh B, Fu FH, Huard J. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthr Cartil. 2013;21:175–85.
  4. Yelin E, Weinstein S, King T. The burden of musculoskeletal diseases in the United States. Semin Arthritis Rheum. 2016; doi:10.1016/jsemarthrit201607013.
  5. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226–9. doi:10.1002/ art21562.
  6. Castricini R, Longo UG, de Benedetto M, PanfoliN,Pirani P, Zini R, Maffulli N, Denaro V. Platelet-richplasma augmentation for arthroscopic rotator cuffrepair: a randomized controlled trial. Am J SportsMed. 2011;39:258–65.
  7. Hall MP, Band PA, Meislin RJ, Jazrawi LM, Cardone DA. Platelet-rich plasma: current concepts and application in sports medicine. J Am AcadOrthop Surg. 2009;17:602–8.
  8. Mifune Y, Matsumoto T, Takayama K, Ota S, Li H, Meszaros LB, Usas A, Nagamune K, Gharaibeh B, Fu FH, Huard J. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthr Cartil. 2013;21:175–85.
  9. Zhu Y, Yuan M, Meng HY, Wang AY, Guo QY, Wang Y, et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthr Cartil. 2 0 1 3 ; 2 1 ( 1 1 ) : 1627–37.
  10. Ehrenfest D, et al. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte – and platelet-rich fibrin (L-PRF). Trends Biotechnology 2009; 27(3): 158-167.
  11. Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016;44:792–800.
  12. Mazzocca AD, Mccarthy MB, Chowaniec DM, Cote MP, Romeo AA, Bradley JP, Arciero RA, Beitzel K. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94:308–16.
  13. LaPrade RF, Geeslin AG, Murray IR, Musahl V, Zlotnicki JP, Petrigliano F, et al. Biologic treatments for sports injuries II think tank-current concepts, future research, and barriers to advancement, part 1: biologics overview, ligament injury, tendinopathy. Am J Sports Med. 2016
  14. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res. 2003;52(10):404e7.
  15. Marx R. Platelet-rich plasma: evidence to support its use. Oral Maxillofac Surg 2004; 62(4): 489-496.
  16. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration  from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39:266–71.
  17. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259–72.
  18. Angoorani H, Mazaherinezhad A, Marjomaki O, Younespour S. Treatment of knee osteoarthritis with platelet-rich plasma in comparison with transcutaneous electrical nerve stimulation plus exercise: a randomized clinical trial. Med J Islam Repub Iran. 2015;29:223.
  19. Dhillon M, Patel S, Bali K. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports TraumatolArthrosc. 2011; 19(5):863–4. author reply 5–6
  20. Filardo G, Kon E, Buda R, Timoncini A, Di Martino A, Cenacchi A, et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2011;19(4):528– 35.
  21. Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, et al. Knee osteoarthritis injection choices: platelet- rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8.
  22. Rayegani SM, Raeissadat SA, Taheri MS, Babaee M, Bahrami MH, Eliaspour D, et al. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. Orthop Rev (Pavia). 2014;6(3):5405.
  23. Sampson S, Reed M, Silvers H, Meng M, Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil. 2010;89(12):961–9.
  24. Battaglia M, Guaraldi F, Vannini F, Rossi G, Timoncini A, Buda R, et al. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. Orthopedics. 2013;36(12):e1501–8.
  25. Dallari D, Stagni C, Rani N, Sabbioni G, Pelotti P, Torricelli P, et al. Ultrasound-guided injection of platelet-rich plasma and hyaluronic acid, separately and in combination, for hip osteoarthritis: a randomized controlled study. Am J SportsMed. 2016.
  26. Sanchez M, Guadilla J, Fiz N, Andia I. Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology(Oxford). 2012;51(1):144–50.
  27. Fleming BC, Proffen BL, Vavken P, Shalvoy MR, Machan JT, Murray MM. Increased platelet concentration does not improve functional graft healing in bio-enhanced ACL reconstruction. Knee Surg Sports Traumatol Arthrosc. 2015;23(4):1161–70.
  28. Goodrich LR, Mcilwraith CW. Small molecules alone or in combination to treat joint disease and progress toward gene therapy. Oper Tech Orthop.  2016;26:73–81.
  29. Dragoo JL, Braun HJ, Durham JL, Ridley BA, Odegaard JI, Luong R, et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med. 2012;40(6):1274–81.
  30. Dhillon M, Patel S, Bali K. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports TraumatolArthrosc. 2011; 19(5):863–4. author reply 5–6.
  31. Rai MF, Sandell LJ. Regeneration of articular cartilage in healer and non-healer mice. Matrix Biol. 2014;39:50–5. doi:10.1016/jmatbio201408011.
  32. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration  from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39:266–71.
  33. Goodrich LR, Mcilwraith CW. Small molecules alone or in combination to treat joint disease and progress toward gene therapy. Oper Tech Orthop.  2016;26:73–81.
  34. Kruger JP, Hondke S, Endres M, Pruss A, Siclari A, Kaps C. Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res. 2012;30:845–52.
  35. Mazzocca AD, Mccarthy MB, Chowaniec DM, Cote MP, Romeo AA, Bradley JP, Arciero RA, Beitzel K. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94:308–16.
  36. Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016;44:792–800.
  37. Anz AW, Hackel JG, Nilssen EC, Andrews JR. Application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis. J Am Acad OrthopSurg. 2014;22:68–79.
  38. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–50.
  39. Wang JH, Nirmala X. Application of tendon stem/progenitor cells and platelet-rich plasma to treat tendoninjuries. Oper Tech Orthop. 2016;26:68–72.
  40. Jorgensen C, Noel D. Mesenchymal stem cells in osteoarticular diseases. Regen Med. 2011; 6(6 Suppl):44–51.
  41. ItalianoJr JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008.
  42. Seijas R, Rius M, Ares O, Garcia-Balletbo M, SerraI, Cugat R. Healing of donor site in bone-tendon-boneACL reconstruction accelerated with plasmarich in growth factors: a randomized clinical trial. Knee Surg Sports TraumatolArthrosc.2015;23:991–7.
  43. Tate ML, Adamson JR, Tami AE, Bauer TW. Cells in focus, the osteocyte. Int J Biochem Cell Biol.2004;36:1–8.
  44. Sackmann E. Biological membranes architecture and function. In: Lipowsky R, Sackmann E, editors. Handbook of biological physics, vol. 1. Amsterdam: Elsevier; 1995.
  45. Cohen CB, Cohen PJ. International stem cell tourism and the need for effective regulation: part i: stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype? Kennedy Inst Ethics J. 2010;20(1):27–49.
  46. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res. 2003;52(10):404e7.
  47. Mifune Y, Matsumoto T, Takayama K, Ota S, Li H, Meszaros LB, Usas A, Nagamune K, Gharaibeh B, Fu FH, Huard J. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthr Cartil. 2013;21:175–85.
  48. Desando, G.; Bartolotti, I.; Cavallo, C.; Schiavinato, A.; Secchieri, C.; Kon, E.; Filardo, G.; Paro, M.; Grigolo, B. Short-Term Homing of Hyaluronan-Primed Cells: Therapeutic Implications for Osteoarthritis Treatment. Tissue Eng. Part C Methods 2017, 24, 121–133.
  49. Pak, J.; Lee, J.H.; Park, K.S.; Jeong, B.C.; Lee, S.H. Regeneration of Cartilage in Human Knee Osteoarthritis with Autologous Adipose Tissue-Derived Stem Cells and Autologous Extracellular Matrix. BioResearch Open Access 2016, 5, 192–200.
  50. Pak, J.; Chang, J.-J.; Lee, J.H.; Lee, S.H. Safety Reporting on Implantation of Autologous Adipose Tissue-Derived Stem Cells with Platelet-Rich Plasma into Human Articular Joints. BMC Musculoskelet. Disord. 2013, 14, 337.
  51. Pak, J. Regeneration of Human Bones in Hip Osteonecrosis and Human Cartilage in Knee Osteoarthritis with Autologous Adipose-Tissue-Derived Stem Cells: A Case Series. J. Med. Case Rep. 2011, 5, 296
  52. Baltzer AWA, et al. Autologous conditioned serum (Orthokine®) is an effectivetreatmentfor knee osteoarthritis. OsteoarthrCartil. 2009;17(2):152–60.
  53. Auw Yang KG, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. OsteoarthrCartil. 2008;16(4):498–505.
  54. Mifune Y, Matsumoto T, Takayama K, Ota S, Li H, Meszaros LB, Usas A, Nagamune K, Gharaibeh B, Fu FH, Huard J. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthr Cartil. 2013;21:175–85.
  55. Astolfi M, et al. The effectiveness of autologous conditioned serum in the treatment of knee osteoarthritis. J Sport Rehabil. 2014;23:365–9.
  56. Evans CH, et al. Autologous conditioned serum. Phys Med RehabilClin N Am. 2016;27:893–908.
  57. Frizziero A, et al. Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders. Br Med Bull. 2013;105:169–84.
  58. Wehling P, et al. How does surgery compare with advanced intra-articular therapies in knee osteoarthritis: current thoughts. Ther Adv Musculoskelet Dis. 2016;8(3):72–85.
  59. Wilmer L Sibbitt Jr, Andres Peisajovich, Adrian A Michael, Kye S Park, Randy R Sibbitt, Philip A Band, Arthur D Bankhurst. Does sonographic needle guidance affect the clinical outcome of intraarticular injections? J Rheumatol 2009 Sep;36(9):1892-902.
  60. Griffin JW, Hadeed MM, Werner BC, Diduch DR, Carson EW, Miller MD. Platelet-rich plasma in meniscal repair: does augmentation improve surgical outcomes? ClinOrthopRelat Res. 2015;473(5):1665– 72.
  61. Gaumet M, Badoud I, Ammann P, Long-term beneficial effect of hyaluronic acid viscosupplements on cartilage quality, P689, WCO-IOF-ESCEO, Krakow, Poland, 19–22 April 2018, P 256, OARSI, Liverpool, UK, 26–29 April 2018.

 

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.
Финансирование. Исследование не имело спонсорской поддержки.
Участие авторов. Cтатья подготовлена с равным участием авторов.
Поступила: 17.01.2024. Принята к публикации: 16.02.2024. 

 

© 2025 Научный журнал – «Клинический вестник ФМБЦ им. А.И. Бурназяна»
Прокрутить наверх